ZA201908245B - Transgenic macrophages, chimeric antigen receptors, and associated methods - Google Patents
Transgenic macrophages, chimeric antigen receptors, and associated methodsInfo
- Publication number
- ZA201908245B ZA201908245B ZA2019/08245A ZA201908245A ZA201908245B ZA 201908245 B ZA201908245 B ZA 201908245B ZA 2019/08245 A ZA2019/08245 A ZA 2019/08245A ZA 201908245 A ZA201908245 A ZA 201908245A ZA 201908245 B ZA201908245 B ZA 201908245B
- Authority
- ZA
- South Africa
- Prior art keywords
- chimeric antigen
- associated methods
- antigen receptors
- macrophages
- transgenic
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title 1
- 210000002540 macrophage Anatomy 0.000 title 1
- 230000009261 transgenic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001162—Kinases, e.g. Raf or Src
-
- A61K39/4614—
-
- A61K39/4622—
-
- A61K39/4631—
-
- A61K39/464404—
-
- A61K39/464406—
-
- A61K39/464417—
-
- A61K39/464422—
-
- A61K39/464454—
-
- A61K39/464462—
-
- A61K39/464468—
-
- A61K39/46447—
-
- A61K39/464471—
-
- A61K39/464482—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/11—Antigen recognition domain
- A61K2239/13—Antibody-based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/21—Transmembrane domain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/55—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2017/033039 WO2018212770A1 (en) | 2017-05-17 | 2017-05-17 | Transgenic macrophages, chimeric antigen receptors, and associated methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201908245B true ZA201908245B (en) | 2020-12-23 |
Family
ID=59078161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2019/08245A ZA201908245B (en) | 2017-05-17 | 2019-12-11 | Transgenic macrophages, chimeric antigen receptors, and associated methods |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3624834A1 (en) |
| JP (2) | JP7164598B2 (en) |
| KR (1) | KR102508182B1 (en) |
| CN (1) | CN110662553A (en) |
| AU (1) | AU2017414703A1 (en) |
| CA (1) | CA3062978A1 (en) |
| WO (1) | WO2018212770A1 (en) |
| ZA (1) | ZA201908245B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10434153B1 (en) | 2015-05-20 | 2019-10-08 | Kim Leslie O'Neill | Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors |
| US11352439B2 (en) | 2015-08-13 | 2022-06-07 | Kim Leslie O'Neill | Macrophage CAR (MOTO-CAR) in immunotherapy |
| WO2018064076A1 (en) | 2016-09-27 | 2018-04-05 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules |
| US10415017B2 (en) | 2017-05-17 | 2019-09-17 | Thunder Biotech, Inc. | Transgenic macrophages, chimeric antigen receptors, and associated methods |
| CN109336980B (en) * | 2017-07-27 | 2022-04-12 | 上海细胞治疗研究院 | Muc 1-targeted chimeric antigen receptor modified T cell and application thereof |
| EP3688032A1 (en) | 2017-09-26 | 2020-08-05 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules and methods of use |
| JP2022547154A (en) | 2019-09-10 | 2022-11-10 | オブシディアン セラピューティクス， インコーポレイテッド | CA2-IL15 fusion proteins for regulatable control |
| KR20220143642A (en) * | 2019-12-11 | 2022-10-25 | 마이얼로이드 테라퓨틱스, 인크. | Therapeutic cell compositions and methods for their preparation and uses |
| CN113980138B (en) * | 2021-08-11 | 2023-08-11 | 卡瑞济(北京)生命科技有限公司 | EphA2 chimeric antigen receptor and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2422956A1 (en) | 1978-04-13 | 1979-11-09 | Pasteur Institut | METHOD OF DETECTION AND CHARACTERIZATION OF A NUCLEIC ACID OR OF A SEQUENCE OF THE SAME, AND ENZYMATIC REAGENT FOR THE IMPLEMENTATION OF THIS PROCESS |
| FR2464269B1 (en) | 1979-08-30 | 1986-04-18 | Anvar | NUCLEOTIDE SEQUENCE ENCODING HEPATITIS B VIRUS SURFACE ANTIGEN, PROCESS FOR OBTAINING SAME AND ANTIGEN OBTAINED |
| FR2518755B1 (en) | 1981-12-23 | 1986-04-11 | Pasteur Institut | PROBE CONTAINING MODIFIED NUCLEIC ACID RECOGNIZABLE BY SPECIFIC ANTIBODIES AND USE OF THE SAME TO DETECT AND CHARACTERIZE A HOMOLOGATED DNA SEQUENCE |
| CA3225456A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| IL297905A (en) | 2015-07-28 | 2023-01-01 | Univ Pennsylvania | Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof |
| WO2017025944A2 (en) * | 2015-08-13 | 2017-02-16 | Brigham Young University | Macrophage car (moto-car) in imunotherapy |
-
2017
- 2017-05-17 KR KR1020197037141A patent/KR102508182B1/en active IP Right Grant
- 2017-05-17 WO PCT/US2017/033039 patent/WO2018212770A1/en unknown
- 2017-05-17 JP JP2020514655A patent/JP7164598B2/en active Active
- 2017-05-17 CA CA3062978A patent/CA3062978A1/en active Pending
- 2017-05-17 CN CN201780090935.5A patent/CN110662553A/en active Pending
- 2017-05-17 EP EP17731332.7A patent/EP3624834A1/en active Pending
- 2017-05-17 AU AU2017414703A patent/AU2017414703A1/en active Pending
-
2019
- 2019-12-11 ZA ZA2019/08245A patent/ZA201908245B/en unknown
-
2022
- 2022-10-19 JP JP2022167762A patent/JP2022189893A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022189893A (en) | 2022-12-22 |
| JP2020520252A (en) | 2020-07-09 |
| AU2017414703A1 (en) | 2020-01-16 |
| CN110662553A (en) | 2020-01-07 |
| KR102508182B1 (en) | 2023-03-09 |
| KR20200020708A (en) | 2020-02-26 |
| WO2018212770A1 (en) | 2018-11-22 |
| CA3062978A1 (en) | 2018-11-22 |
| EP3624834A1 (en) | 2020-03-25 |
| JP7164598B2 (en) | 2022-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275619A (en) | Enhanced chimeric antigen receptors and uses thereof | |
| IL274921A (en) | Bcma-targeting chimeric antigen receptor, and uses thereof | |
| IL274617A (en) | Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies | |
| ZA201908245B (en) | Transgenic macrophages, chimeric antigen receptors, and associated methods | |
| IL263626A (en) | Chimeric antigen receptors and methods for use | |
| SG11202000555UA (en) | Chimeric antigen receptors (cars), compositions and methods thereof | |
| HK1252854A1 (en) | Kappa myeloma antigen chimeric antigen receptors and uses thereof | |
| EP3658163A4 (en) | Enhanced chimeric antigen receptors and use thereof | |
| IL250536A0 (en) | Chimeric antigen receptors | |
| IL251030A0 (en) | Chimeric antigen receptors | |
| IL270896A (en) | Chimeric antigen receptors targeting flt3 | |
| IL281097A (en) | Chimeric antigen receptors against multiple hla-g isoforms | |
| GB201607968D0 (en) | Chimeric antigen receptor | |
| GB201610512D0 (en) | Chimeric antigen receptor | |
| ZA201906321B (en) | Chimeric antigen receptor | |
| ZA202005837B (en) | Cd83-binding chimeric antigen receptors | |
| IL281129A (en) | Methods and compositions comprising b7h3 chimeric antigen receptors | |
| EP3585403A4 (en) | Tim3-binding chimeric antigen receptors | |
| GB201709508D0 (en) | Chimeric antigen receptor | |
| GB201711470D0 (en) | Chimeric receptors | |
| GB2585607B (en) | Chimeric antigen receptor and application thereof | |
| GB201810451D0 (en) | Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof | |
| GB201721421D0 (en) | Chimeric antigen receptor | |
| GB201612844D0 (en) | Chimeric antigen receptor | |
| GB201612533D0 (en) | Chimeric antigen receptor |